EP4065227A4 - BRAIN REGENERATION AFTER TRAUMATIC BRAIN INJURY BY NEUROD1-MEDIATED ASTROCYTE-TO-NEURON CONVERSION - Google Patents

BRAIN REGENERATION AFTER TRAUMATIC BRAIN INJURY BY NEUROD1-MEDIATED ASTROCYTE-TO-NEURON CONVERSION Download PDF

Info

Publication number
EP4065227A4
EP4065227A4 EP20894844.8A EP20894844A EP4065227A4 EP 4065227 A4 EP4065227 A4 EP 4065227A4 EP 20894844 A EP20894844 A EP 20894844A EP 4065227 A4 EP4065227 A4 EP 4065227A4
Authority
EP
European Patent Office
Prior art keywords
neurod1
astrocytes
neurons
repair
mediated conversion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20894844.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4065227A1 (en
Inventor
Gong Chen
Zhou-Fan LEI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of EP4065227A1 publication Critical patent/EP4065227A1/en
Publication of EP4065227A4 publication Critical patent/EP4065227A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20894844.8A 2019-11-25 2020-11-25 BRAIN REGENERATION AFTER TRAUMATIC BRAIN INJURY BY NEUROD1-MEDIATED ASTROCYTE-TO-NEURON CONVERSION Withdrawn EP4065227A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939978P 2019-11-25 2019-11-25
PCT/US2020/062299 WO2021108609A1 (en) 2019-11-25 2020-11-25 Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion

Publications (2)

Publication Number Publication Date
EP4065227A1 EP4065227A1 (en) 2022-10-05
EP4065227A4 true EP4065227A4 (en) 2023-12-20

Family

ID=76130727

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20894844.8A Withdrawn EP4065227A4 (en) 2019-11-25 2020-11-25 BRAIN REGENERATION AFTER TRAUMATIC BRAIN INJURY BY NEUROD1-MEDIATED ASTROCYTE-TO-NEURON CONVERSION

Country Status (6)

Country Link
EP (1) EP4065227A4 (https=)
JP (1) JP2023502782A (https=)
CN (1) CN115135382A (https=)
AU (1) AU2020391479A1 (https=)
CA (1) CA3162891A1 (https=)
WO (1) WO2021108609A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120418229A (zh) * 2022-12-28 2025-08-01 安斯泰来制药株式会社 4-氨基哌啶化合物、其脂质纳米粒子和含有其的药物组合物
WO2024162304A1 (ja) * 2023-01-31 2024-08-08 アステラス製薬株式会社 環状アミンを有するカルバモイル脂質又はウレア脂質、それを含む脂質ナノ粒子、及び医薬組成物
WO2025143118A1 (ja) * 2023-12-27 2025-07-03 アステラス製薬株式会社 脊髄損傷の治療用医薬組成物及び脊髄損傷の非ヒト霊長類動物モデルの作製方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903933A1 (en) * 2015-09-11 2017-03-11 Nomadogen Biotechnologies Inc. Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
US20170073382A1 (en) * 2015-09-11 2017-03-16 Nomadogen Biotechnologies Inc. Methods and Compositions For The Packaging of Nucleic Acids Into Microglial Exosomes For The Targeted Expression of Polypeptides in Neural Cells
WO2019152857A1 (en) * 2018-02-02 2019-08-08 Gong Chen Methods and materials for treating brain injuries

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087168A (en) * 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
US10561742B2 (en) * 2012-07-19 2020-02-18 The Penn State Research Foundation Methods and compositions for treatment of disease or injury of the nervous system
US10076574B2 (en) * 2013-10-25 2018-09-18 Wayne State University Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
US10973930B2 (en) * 2016-02-18 2021-04-13 The Penn State Research Foundation Generating GABAergic neurons in brains
US20200054711A1 (en) * 2017-02-28 2020-02-20 The Penn State Research Foundation Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903933A1 (en) * 2015-09-11 2017-03-11 Nomadogen Biotechnologies Inc. Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
US20170073382A1 (en) * 2015-09-11 2017-03-16 Nomadogen Biotechnologies Inc. Methods and Compositions For The Packaging of Nucleic Acids Into Microglial Exosomes For The Targeted Expression of Polypeptides in Neural Cells
WO2019152857A1 (en) * 2018-02-02 2019-08-08 Gong Chen Methods and materials for treating brain injuries

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LETHBRIDGE BRAINIACS: "Team:Lethbridge/project - 2014.igem.org", 2 July 2015 (2015-07-02), XP055652357, Retrieved from the Internet <URL:https://web.archive.org/web/20150702194117/http://2014.igem.org/Team:Lethbridge/project> [retrieved on 20191212] *
See also references of WO2021108609A1 *
WESTON NICOLE M ET AL: "The Potential of Stem Cells in Treatment of Traumatic Brain Injury", CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, SPRINGER US, NEW YORK, vol. 18, no. 1, 25 January 2018 (2018-01-25), pages 1 - 10, XP036423434, ISSN: 1528-4042, [retrieved on 20180125], DOI: 10.1007/S11910-018-0812-Z *

Also Published As

Publication number Publication date
JP2023502782A (ja) 2023-01-25
CN115135382A (zh) 2022-09-30
CA3162891A1 (en) 2021-06-03
WO2021108609A1 (en) 2021-06-03
AU2020391479A1 (en) 2022-06-16
EP4065227A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
IL280919A (en) Methods of treating aging-related disorders
EP4065227A4 (en) BRAIN REGENERATION AFTER TRAUMATIC BRAIN INJURY BY NEUROD1-MEDIATED ASTROCYTE-TO-NEURON CONVERSION
ZA201903581B (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
EP3830130A4 (en) Muscle targeting complexes and uses thereof for treating centronuclear myopathy
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
EP3397261C0 (en) SUB-MITOCHONDRIAL PARTICLES FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
EP3478287A4 (en) TREATMENT OF SEPTICEMIA AND ASSOCIATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMOUS NERVOUS SYSTEM
MX369749B (es) Método cosmético para reducir las señales dermatológicas de envejecimiento.
DK3442513T3 (da) Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser
EA201892008A1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
EP3484526A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASE
EP3542622A4 (en) SYSTEM FOR THE ELIMINATION OF PARASITES THAT ADHER TO FISH BY DIRECT APPLICATION OF ELECTRICITY TO FISH WHICH ELIMINATES THE ELIMINATION OF PARASITES WITHOUT INJURING THE FISH
EP3581185A4 (en) COMPOSITION CONTAINING URSODESOXYCHOLIC ACID FOR THE PREVENTION OR TREATMENT OF VISUAL IMPAIRMENT
DK3934637T3 (da) (n-)acetyl-l-leucin til anvendelse til behandling af traumatisk hjerneskade
EP3934631C0 (en) CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
EP3775263A4 (en) COMPOSITIONS AND METHODS OF TREATING ACNE
EP3542822A4 (en) PROCESS FOR THE PRODUCTION OF MYOCARDIAL STEM CELL USED FOR THE TREATMENT AND / OR PREVENTION OF HEART ARREST
SI3478719T1 (sl) Uporaba protiteles proti sklerostinu pri zdravljenju osteogenesis imperfecte
EP3429598A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH BETA-CATENIN
IL269641A (en) Preparations and methods for the treatment of complications and disorders related to Factor One and Liebrand
EP3595669A4 (en) USE OF TAILOR-MADE RECEPTORS ACTIVATED EXCLUSIVELY BY CUSTOM-MADE MEDICINES IN THE TREATMENT OF EPILEPTIC DISORDERS
EP3373980A4 (en) Methods of treating muscular dystrophy
EP4399311A4 (en) APP ARNI COMPOSITIONS AND THEIR METHODS OF USE FOR TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ENLARGED ENDOSOMES
EP3288550C0 (en) STRUCTURALLY IMPROVED SULFUR-CONTAINING FATTY ACIDS FOR USE IN THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE
EP3395341C0 (en) COMPOSITION FOR THE TREATMENT OF NEUROMOTOR DISEASES AND ITS USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20231113BHEP

Ipc: C07K 14/48 20060101ALI20231113BHEP

Ipc: C07K 14/47 20060101ALI20231113BHEP

Ipc: A61P 25/00 20060101AFI20231113BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250513